# A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

> **NCT04344158** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 648 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** AK105 Injection
- **DRUG:** Anlotinib Hydrochloride Capsules
- **DRUG:** Sorafenib Tosylate Tablets

## Key facts

- **NCT ID:** NCT04344158
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-11
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 648 (ESTIMATED)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04344158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04344158, "A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04344158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*